Canaccord Genuity Maintains Buy on MapLight Therapeutics, Lowers Price Target to $24

Benzinga Newsdesk www.benzinga.com Negative 71.5%

Neg 71.5% Neu 0% Pos 0%

Canaccord Genuity analyst Sumant Kulkarni maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and lowers the price target from $43 to $24.